Klaus Veitinger
Chairman bei TRICIDA, INC.
Vermögen: - $ am 31.03.2024
Profil
Klaus R.
Veitinger is currently the Chairman at Promentis Pharmaceuticals, Inc., Tricida, Inc., Neurogastrx, Inc., Sparrow Pharmaceuticals, Inc., and scPharmaceuticals, Inc. He is also an Independent Director at scPharmaceuticals, Inc. Additionally, Dr. Veitinger is a Venture Partner at OrbiMed Advisors Private Equity.
In his former positions, Dr. Veitinger served as the Director & Chief Executive Officer at Symbiomix Therapeutics LLC, President & Chief Executive Officer at Schwarz Pharma, Inc., Vice Chairman at Relypsa, Inc., and an Independent Director at Intercept Pharmaceuticals, Inc. He also held director positions at Bone Care International, Inc., Biolex Therapeutics, Inc., Gelesis, Inc., Chroma Therapeutics Ltd., and the Pharmaceutical Research & Manufacturers of America.
Dr. Veitinger was a Member-Management Board at UCB Pharma GmbH.
Dr. Veitinger obtained a doctorate degree from Heidelberg University (Ohio) and an MBA from INSEAD.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SCPHARMACEUTICALS, INC.
-.--% | 29.02.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Klaus Veitinger
| Unternehmen | Position | Beginn |
|---|---|---|
| TRICIDA, INC. | Chairman | 01.09.2015 |
| SCPHARMACEUTICALS INC. | Director/Board Member | 21.11.2017 |
Promentis Pharmaceuticals, Inc.
 Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | Chairman | 01.04.2008 |
Neurogastrx, Inc.
 Neurogastrx, Inc. BiotechnologyHealth Technology Neurogastrx, Inc. operates as a venture-stage biopharmaceutical company. The firm develops biopharmaceutical products for the treatment of gastrointestinal disorders. It offers NG101, a product for the treatment of gastroparesis. The company was founded by Cyril De Colle and Pankaj Jay Pasricha and is headquartered in Campbell, CA. | Chairman | 04.01.2018 |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Private Equity Investor | 04.01.2011 |
Sparrow Pharmaceuticals, Inc.
 Sparrow Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sparrow Pharmaceuticals, Inc. engages in pharmaceuticals industry. It develops drugs for cushing?s syndrome. The company was founded by David A. Katz and is headquartered in Portland, OR. | Chairman | - |
Ehemalige bekannte Positionen von Klaus Veitinger
| Unternehmen | Position | Ende |
|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Director/Board Member | 01.07.2016 |
Symbiomix Therapeutics LLC
 Symbiomix Therapeutics LLC BiotechnologyHealth Technology Symbiomix Therapeutics LLC develops medicines for women’s health infections and related diseases. It offers SYM-1219, a drug that contains secnidazole that facilitate administration as a single-dose oral therapy for various women's health infections including bacterial vaginosis. The company was founded by Jack Roberts, Steve Pomerantz and Joseph L. Amprey III in 2012 and is headquartered in Newark, NJ. | Chief Executive Officer | 01.12.2015 |
| RELYPSA INC | Director/Board Member | 01.06.2015 |
| ░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Klaus Veitinger
| Heidelberg University (Ohio) | Doctorate Degree |
| INSEAD | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| TRICIDA, INC. | Health Technology |
| SCPHARMACEUTICALS INC. | Health Technology |
| Private Unternehmen | 13 |
|---|---|
Bone Care International, Inc.
 Bone Care International, Inc. Pharmaceuticals: OtherHealth Technology Bone Care International, Inc. developed innovative therapeutic products. Its products included Hectorol Injections and Capsules. The company was located in Middleton, WI. | Health Technology |
UCB Pharma GmbH
 UCB Pharma GmbH Pharmaceuticals: MajorHealth Technology UCB Pharma GmbH manufactures and develops drugs. It manufactures prescription and non-prescription drugs. With its partners, the company engages in biopharmaceutical research and development. Apart from providing medication, the company provides support to the patients. The company was founded in 1928 and is headquartered in Monheim, Germany. | Health Technology |
Biolex Therapeutics, Inc.
 Biolex Therapeutics, Inc. Medical DistributorsDistribution Services Biolex Therapeutics, Inc. developed and produced drugs. The company was founded in 1997 and was headquartered in Pittsboro, NC. | Distribution Services |
Gelesis, Inc.
 Gelesis, Inc. BiotechnologyHealth Technology Gelesis, Inc. operates as a consumer-centered biotherapeutics company, which engages in the development of novel therapies to induce weight loss and metabolic disorders. Its commercial product portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease /Non-alcoholic Steatohepatitis, and Functional Constipation. The company was founded by Yishai Zohar in 2006 and is headquartered in Boston, MA. | Health Technology |
Promentis Pharmaceuticals, Inc.
Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | Health Technology |
Symbiomix Therapeutics LLC
Symbiomix Therapeutics LLC BiotechnologyHealth Technology Symbiomix Therapeutics LLC develops medicines for women’s health infections and related diseases. It offers SYM-1219, a drug that contains secnidazole that facilitate administration as a single-dose oral therapy for various women's health infections including bacterial vaginosis. The company was founded by Jack Roberts, Steve Pomerantz and Joseph L. Amprey III in 2012 and is headquartered in Newark, NJ. | Health Technology |
Chroma Therapeutics Ltd.
 Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Schwarz Pharma, Inc.
 Schwarz Pharma, Inc. Pharmaceuticals: MajorHealth Technology SCHWARZ PHARMA, Inc. develops and manufactures pharmaceutical products. The company's products include Codimal, Colyte, Edex, Kutrase, Levatol, Robaxin, and Verelan. It was founded in 2003 and is headquartered in Mequon, WI. | Health Technology |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Health Technology |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Finance |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
Neurogastrx, Inc.
Neurogastrx, Inc. BiotechnologyHealth Technology Neurogastrx, Inc. operates as a venture-stage biopharmaceutical company. The firm develops biopharmaceutical products for the treatment of gastrointestinal disorders. It offers NG101, a product for the treatment of gastroparesis. The company was founded by Cyril De Colle and Pankaj Jay Pasricha and is headquartered in Campbell, CA. | Health Technology |
Sparrow Pharmaceuticals, Inc.
Sparrow Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sparrow Pharmaceuticals, Inc. engages in pharmaceuticals industry. It develops drugs for cushing?s syndrome. The company was founded by David A. Katz and is headquartered in Portland, OR. | Health Technology |
